文献速递流行病学与生物统计临床试验与 GCP

解读精神健康临床试验结果文章时为何需要谨慎

Why prudence is needed when interpreting articles reporting clinical trial results in mental health.
PubMed 文献 · Trials · 2017-03-28

精神健康试验因样本量小和使用需主观评估的心理测量量表而易产生不可靠结果,发表偏倚和结局报告偏倚在心理治疗与药物治疗试验中均较常见,并可传递至荟萃分析。前瞻性注册试验和发表结果是减少报告偏倚的两大方法,但精神健康干预试验的注册率低且质量常不佳。临床医生解读已发表试验及部分荟萃分析时应谨慎,但按产品特征摘要处方药物时可保持信心,因监管机构可获取全部临床试验结果。

要点

  • 精神健康试验常因样本量小和主观量表评估而易产生假阳性及效应量夸大。
  • 心理治疗和药物治疗试验中均发现相当程度的报告偏倚,并可传递至荟萃分析。
  • 前瞻性注册和发表结果是减少报告偏倚的主要方法,但精神健康干预试验注册率低且质量常不佳。

核心结论

  • 临床医生解读已发表试验及部分荟萃分析时应谨慎,例如由申办公司科学家开展或仅纳入已发表试验的荟萃分析。
  • 处方者按产品特征摘要处方药物时可保持信心,因监管机构可获取全部临床试验结果。

研究设计与样本

  • 原文为针对精神健康临床试验结果解读的论述性文章,未报告系统检索范围或样本量。

主要发现

  • 精神健康试验易出现两种方法学缺陷:使用少量参与者易致假阳性发现和效应量夸大,以及必须使用需主观评估的心理测量量表。
  • 心理治疗和药物治疗试验的安全性及有效性结果中均发现相当程度的报告偏倚。
  • 报告偏倚可传递至荟萃分析,而荟萃分析是临床实践指南的关键来源,最终常导致治疗效应被高估,可能影响患者和临床医生知情决策。
  • 精神健康干预试验的注册率低且注册质量常不佳。

临床怎么用

  • 临床医生解读已发表试验及部分荟萃分析时应谨慎,例如由申办公司科学家开展或仅纳入已发表试验的荟萃分析。
  • 处方者按产品特征摘要处方药物时可保持信心,因监管机构可获取全部临床试验结果。
  • 前瞻性试验注册可核查试验是否发表,从而帮助预防发表偏倚;若已发表,可核查试验启动前认定的结局和分析是否实际发表,从而帮助发现选择性结局报告。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trial results' reliability is impacted by reporting bias. This is primarily manifested as publication bias and outcome reporting bias. MENTAL HEALTH TRIALS' SPECIFIC FEATURES: Mental health trials are prone to two methodological deficiencies: (1) using small numbers of participants that facilitates false positive findings and exaggerated size effects, and (2) the obligatory use of psychometric scales that require subjective assessments. These two deficiencies contribute to the publication of unreliable results. Considerable reporting bias has been found in safety and efficacy findings in psychotherapy and pharmacotherapy trials. Reporting bias can be carried forward to meta-analyses, a key source for clinical practice guidelines. The final result is the frequent overestimation of treatment effects that could impact patients and clinician-informed decisions. MECHANISMS TO PREVENT OUTCOME REPORTING BIAS: Prospective registration of trials and publication of results are the two major methods to reduce reporting bias. Prospective trial registration will allow checking whether they are published (so it will help to prevent publication bias) and, if published, whether those outcomes and analyses that were deemed as appropriate before trial commencement are actually published (hence helping to find out selective reporting of outcomes). Unfortunately, the rate of registered trials in mental health interventions is low and, frequently, of poor quality. CONCLUSION: Clinicians should be prudent when interpreting the results of published trials and some meta-analyses - such as those conducted by scientists working for the sponsor company or those that only include published trials. Prescribers, however, should be confident when prescribing drugs following the summary of product characteristics, since regulatory agencies have access to all clinical trial results.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dal-Ré R, Bobes J, Cuijpers P, et al. Why prudence is needed when interpreting articles reporting clinical trial results in mental health. Trials. 2017. PMID: 28351418. doi:10.1186/s13063-017-1899-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。